The Catch Hiding In Eli Lilly Stock’s Growth Story

Eli Lilly’s obesity drug franchise is a juggernaut, but a surprisingly large share of its success relies on price-sensitive consumers.

After a run that has seen it post a 45% gain over the last 12 months, it’s hard to find a flaw in the Eli Lilly (LLY) story. The stock sits at its high, powered by large growth from its new class of medicines. But when a company’s valuation is this stretched, you have to look past the headline numbers for signs of vulnerability.

For Lilly, the most revealing number isn’t total revenue or profit margins. It’s the percentage of new patients for its blockbuster obesity drug, Zepbound, who are paying for it themselves, out-of-pocket. That single figure tells a more complicated story than the rapid top-line growth suggests.

The Double-Edged Sword Of Self-Pay

On the surface, a high number of cash-paying customers is a sign of incredible demand. And the number is indeed high. In the most recent quarter, management noted that the self-pay channel accounted for a remarkable 55% of new prescriptions for its key obesity drug. That’s up slightly from the prior quarter, when self-pay vials represented nearly 50% of new prescriptions.

This is where the good news ends and the risk begins. While this demand is fueling Lilly’s incredible growth, it’s not the kind of sticky, high-quality revenue that typically supports a premium valuation. These are customers operating outside the traditional insurance system, and that makes them a fundamentally different and riskier base to build on.

Why Cash Customers Are A Risk

Think of insured patients as subscribers. A formulary manages its access, a co-pay buffers its costs, and its loyalty is reinforced by the system. Self-pay patients, by contrast, are transactional customers. They are free agents, making a new purchasing decision every month.

This exposes a significant portion of Lilly’s revenue to two key risks: price sensitivity and competition. Cash-pay customers are the most likely to balk at price, seek out cheaper alternatives, or simply stop treatment if their personal financial situation changes. They have no insurance plan, creating a moat around Zepbound. Their decisions are strictly driven by personal affordability, making this revenue stream far less durable than one anchored by broad commercial insurance coverage.

What’s Riding On This Number

A high self-pay mix is the clearest evidence of the primary challenge facing Lilly: converting this initial wave of demand into a stable, long-term, insured patient population. The company’s stock, trading at a price-to-sales multiple of 14, appears to price in years of sustained, predictable growth. A heavy reliance on the highly variable customer segment directly challenges that assumption.

The franchise is a large growth engine, with Zepbound and Mounjaro contributing $6.7 billion of growth. But with 55% of new patients coming from the cash market, the quality of that growth is worth questioning. The long-term health of the franchise depends on migrating these patients from self-pay models to recurring, insured coverage to a recurring, reimbursed one.

For an investor, total sales tell only part of the story. The more revealing number to watch is the slow, steady decline of that self-pay percentage. If that figure remains stubbornly high, it could signal that the all-important transition to a more durable, insured market is stalling. And for a stock priced for perfection, that would be a genuine reason for concern.

Don’t Bet It All On One Number

That is the risk of owning any single stock: your outcome rests on one company getting it right. You do not have to concentrate risk that way. Rather than depend on Eli Lilly alone, the Trefis High Quality (HQ) Portfolio spreads exposure across 30 high-quality stocks and re-balances them with discipline, so that no single name carries an outsized share of your returns, and it has a track record of outpacing the S&P 500, S&P Mid-cap, and Russell 2000. If the risk we just walked through gives you pause, a diversified alternative like this is worth a serious look.